Peptides and combination of peptides for use in immunotherapy against various tumors

Patent metadata

Field	Value
Publication number	US-11434274-B2
Application number	US-202217698426-A
Country	US
Kind code	B2
Filing date	Mar 18, 2022
Priority date	Mar 27, 2015
Publication date	Sep 6, 2022
Grant date	Sep 6, 2022

Abstract

A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

First claim

The invention claimed is:

1. A method of treating a patient who has colorectal cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of VIIQNLPAL (SEQ ID NO: 195).

2. The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

3. The method of claim 1 , wherein the T cells are autologous to the patient.

4. The method of claim 1 , further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

5. The method of claim 4 , wherein the adjuvant is IL-2.

6. The method of claim 4 , wherein the adjuvant is IL-4.

7. The method of claim 4 , wherein the adjuvant is IL-7.

8. The method of claim 4 , wherein the adjuvant is IL-12.

9. The method of claim 4 , wherein the adjuvant is IL-15.

10. The method of claim 4 , wherein the adjuvant is IL-21.

11. A method of eliciting an immune response in a patient who has colorectal cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of VIIQNLPAL (SEQ ID NO: 195).

12. The method of claim 11 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

13. The method of claim 11 , wherein the T cells are autologous to the patient.

14. The method of claim 11 , further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

15. The method of claim 14 , wherein the adjuvant is IL-2.

16. The method of claim 14 , wherein the adjuvant is IL-4.

17. The method of claim 14 , wherein the adjuvant is IL-7.

18. The method of claim 14 , wherein the adjuvant is IL-12.

19. The method of claim 14 , wherein the adjuvant is IL-15.

20. The method of claim 14 , wherein the adjuvant is IL-21.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Stevermann Lea

Classifications

• G01N2500/10

  involving cells · CPC title

• G01N2333/70539

  MHC-molecules, e.g. HLA-molecules · CPC title

• G01N2333/7051

  T-cell receptor (TcR)-CD3 complex · CPC title

• G01N2333/70503

  Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3 · CPC title

• G01N2333/47

  Assays involving proteins of known structure or function as defined in the subgroups · CPC title